Sagimet BiosciencesSGMT
Recorded

Sagimet Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezAnalyst

Innovation Conference, this is 2026. Really pleased to have Sagimet Biosciences with us. Dave Happel, CEO, and Andreas Grauer, the Chief Medical Officer. This is a company that we've really enjoyed watching the evolution of the story towards acne in particular. Dave, maybe just to kind of kick us off, talking about that strategic pivot, towards the end of April, the ongoing phase III right now. Just provide us your thoughts initially, before we jump into Q&A.

David HappelCEO

Yeah. Thanks, Seamus, and thank you for the invitation to come out. Yes, we made a shift in focus on our dermatology programs back in April, and it was really driven by, I think, a few things, three factors. One, obviously, the market in acne is significant. 50 million patients in the U.S. have acne. 20% of them have moderate to severe acne. So roughly, you'll see numbers around 10 to 15 million. But less than half of them right now are currently being treated with agents like oral antibiotics, which everyone understands we've got to move away from, and topicals. So the market size is rather significant. Well, then of course, you have to have data that can be meaningful to that patient population.

David HappelCEO

Our partner in China, Ascletis, has run a couple of clinical studies, a phase II and a phase III, that show virtually identical results with roughly 20% improvements in IGA success and 20% reductions in inflammatory and non-inflammatory lesions. So, the data is clearly there. We took that data to the FDA last year, and they responded very favorably. They recognized that the pathology of acne is absolutely agnostic to demographic or ethnic background, so that was an important consideration. Two, they aligned on conducting a single phase III study, as long as it was adequately powered, and ours is, which I'm sure Andreas will talk about. Then I think three, and perhaps most importantly, they encouraged us to, once we launched a phase III study, to include 12 to 17-year-olds. They had cross-referenced our end of phase II discussions with the hepatology division in MASH.

David HappelCEO

They recognized that the molecule is extremely well-characterized at this point, has a really nice safety tolerability profile. And all of those three things really aligned then very nicely to make the decision to shift our focus on dermatology, and the market resonated and received that very favorably. We raised $175 million in April to carry us through 2028, and then just recently, as you know, we raised another $115 million through a reverse inquiry that came in that has us well-capitalized through the data readout with denifanstat next year at this time. It funds our second oral FASN inhibitor, which is set to kick off here by the end of this year, and we'll have data from that phase II program at about the same time next year as we have the phase III data.

David HappelCEO

It allows us to take our topical FASN inhibitor through development and into humans. It has been a great time, exciting time, and it has been well-received.

Seamus FernandezAnalyst

Andreas, you have a lot going on and a lot to do. Maybe just in terms of how FASN inhibition is differentiated from other mechanisms in acne, maybe you can just kick off there and remind us, what is it that patients and physicians are kind of struggling with today?

Andreas GrauerChief Medical Officer

Well, complex question. Let me unpack that a little.

Andreas GrauerChief Medical Officer

Yeah Right? Start with the mechanism.

Andreas GrauerChief Medical Officer

What FASN inhibition, what denifanstat does, is something very specific. It inhibits fatty acid synthase. It is an enzyme inhibitor, which, rather than some of the other drugs like anti-androgens that work on all kinds of bodily functions, this has a very specific action. So it is precise. It affects this enzyme where this enzyme is important, which includes the sebocyte, the cell that produces sebum, which is why it is so useful and specific in acne. It also works on liver cells, where it reduces liver fat production. But the effect on the sebocyte is what is important here for acne. When you compare that to other mechanisms of action, like the antibiotics, obviously, they are addressing the infection part as one of the pathogenetic drivers in acne.

Andreas GrauerChief Medical Officer

Anti-androgens, again, they also attack sebum, but only as one of many, many actions that anti-androgens have across the body, which is where you would rather have something more specific, right? Accutane, complex mechanism of action, again, a retinoic acid activator, right? A very complex mechanism of action. It does all kinds of things in the body. Many of them we do not like all that much. If you look at all these various mechanisms, the specificity of FASN inhibition is definitely an asset. When you take that and compare it to the pathogenesis of acne, it is sebum production. It is the key pathogenetic driver, which is the key target of denifanstat. There is inflammation, which is secondary to the bacterial overgrowth, the acne bacteria. Inflammation is also specifically inhibited by FASN inhibition. It is a second important mechanism of FASN inhibition.

Andreas GrauerChief Medical Officer

When you look at the four drivers of acne, increased sebum production, bacterial contamination with acne bacteria, inflammation, and hyperkeratosis, it really tackles two of the four. Hyperkeratosis is somewhat also triggered by all the others, by inflammation and infection. One could postulate that there may be a carryover effect for that as well.

Seamus FernandezAnalyst

Interesting. In terms of the data itself, what have we seen so far from your partner, Ascletis, from the data that has been generated in China? I know there is more than just one trial, but maybe we can focus on the phase III results.

Seamus FernandezAnalyst

Yeah. What did we learn incrementally from the open-label extension?

Andreas GrauerChief Medical Officer

Yeah. Our Chinese partners designed a phase III trial very well, 480 patients, one-to-one randomized. After 12 weeks, the primary endpoint showed a convincing and statistically significant reduction in both the global assessment, the IGA score. Patients achieving treatment success, defined as a reduction of IGA score by at least 2 points, reaching clear or almost clear skin, right? Reaching zero or one. That was highly significant, the effect on that. It also decreased lesion scores, and they looked at all different lesion scores, total inflammatory, non-inflammatory lesion scores, and all of them were reduced significantly at the end of 12 week. When you look at the patient population, they had about 40 inflammatory and 60 non-inflammatory lesions to start with, and again, showed a significant reduction at 12 weeks.

Andreas GrauerChief Medical Officer

That was from an effect size, the improvement in IGA success was at around 20, and the reduction in lesion scores was around 20%, for both inflammatory and non-inflammatory lesions. So very convincing, and while there are no head-to-head trials, numerically better than everything else that we've seen with the current treatments for moderate to severe acne. What is important is when you think about the patient population that was studied here, they had 30 to 75 inflammatory and 30 to 100 non-inflammatory lesions to start with. So moderate to severe acne, IGA 3 and 4. These patients really need help, right? They have significant acne that needs to be improved, and so it's very important to see these effects and also the rapidity of these effects.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day